Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma
- 6 January 2012
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 39 (4) , 569-580
Abstract
To retrospectively evaluate and compare 18F-FDG, 18F-DOPA and 68Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels.Keywords
This publication has 41 references indexed in Scilit:
- Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancerNuclear Medicine Communications, 2010
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid AssociationThyroid®, 2009
- Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancerEndocrine-Related Cancer, 2009
- The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: A prospective studyEuropean Journal of Surgical Oncology, 2008
- New therapeutic approaches to treat medullary thyroid carcinomaNature Clinical Practice Endocrinology & Metabolism, 2008
- Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin LevelsThe Journal of Clinical Endocrinology & Metabolism, 2007
- Imaging of Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid CancerAnnals of Surgical Oncology, 2004
- 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literatureNuclear Medicine Communications, 2004
- Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumoursNuclear Medicine Communications, 1998